# OnCo record bebetter-med (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/bebetter-med/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "bebetter-med" ;
  schema:name "BeBetter Med"@en ;
  schema:alternateName "BeBetter Medicine"@en, "Guangzhou BeBetter Medicine Technology"@en ;
  schema:description "BeBetter Med is a Guangzhou biotechnology company developing BEBT-908, a dual PI3K and HDAC inhibitor for relapsed lymphoma, and other small-molecule cancer drugs, with three late-stage trials in the registry."@en ;
  schema:url <https://onco.cc/companies/bebetter-med/>, <https://www.bebettermed.com/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://www.bebettermed.com/>, <https://clinicaltrials.gov/search?lead=BeBetter%20Med> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "CN" ;
  onco:cancers <https://onco.cc/cancers/dlbcl/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:drugs <https://onco.cc/drugs/bebt-209/>, <https://onco.cc/drugs/ifupinostat/> ;
  onco:trials <https://onco.cc/trials/nct07544056/>, <https://onco.cc/trials/nct06792253/>, <https://onco.cc/trials/nct06998108/>, <https://onco.cc/trials/nct06514027/>, <https://onco.cc/trials/nct06706713/> .